Cutaneous Manifestations of Parry Romberg Syndrome and Complete Resolution with Upadacitinib
Main Article Content
Keywords
parry romberg syndrome,, Janus kinase inhibitor,, upadacitinib
Abstract
Parry Romberg Syndrome (PRS) is a rare, slowly progressive degenerative disorder, marked by the progressive atrophy of facial muscles. Immunosuppressive medications for the treatment of PRS vary in efficacy, and surgical intervention is often utilized for optimal treatment outcomes. Here, we report a case of a 37-year-old female patient with PRS who demonstrated significant improvement after treatment with upadacitinib. The patient presented to the clinic with an indent on the forehead and pain around the area, consistent with Parry Romberg syndrome. Following the initiation of 15mg upadacitnib daily, and a subsequent increase in dosage to 30 mg upadacitinib daily, the indentation on her forehead resolved. This case highlights the utility of Janus kinase inhibitors as an effective treatment for PRS.
References
2 Schultz, K. P., Dong, E., Truong, T. A., & Maricevich, R. S. (2019). Parry Romberg Syndrome. Clinics in plastic surgery, 46(2), 231–237. https://doi.org/10.1016/j.cps.2018.11.007
3 Arif, T., Fatima, R., & Sami, M. (2020). Parry-Romberg syndrome: a mini review. Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 29(4), 193–199.
4 Schultz, K. P., Dong, E., Truong, T. A., & Maricevich, R. S. (2019). Parry Romberg Syndrome. Clinics in plastic surgery, 46(2), 231–237. https://doi.org/10.1016/j.cps.2018.11.007
5 Tolkachjov, S. N., Patel, N. G., & Tollefson, M. M. (2015). Progressive hemifacial atrophy: a review. Orphanet journal of rare diseases, 10, 39. https://doi.org/10.1186/s13023-015-0250-9
6 You, H., Xu, D., Zhao, J., Li, J., Wang, Q., Tian, X., Li, M., & Zeng, X. (2020). JAK Inhibitors: Prospects in Connective Tissue Diseases. Clinical reviews in allergy & immunology, 59(3), 334–351. https://doi.org/10.1007/s12016-020-08786-6
7 Mohamed, M. F., Bhatnagar, S., Parmentier, J. M., Nakasato, P., & Wung, P. (2024). Upadacitinib: Mechanism of action, clinical, and translational science. Clinical and translational science, 17(1), e13688. https://doi.org/10.1111/cts.13688
8 McGaugh, S., Kallis, P., De Benedetto, A., & Thomas, R. M. (2022). Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. Dermatologic therapy, 35(6), e15437. https://doi.org/10.1111/dth.15437
9 Wong, M., Phillips, C. D., Hagiwara, M., & Shatzkes, D. R. (2015). Parry Romberg Syndrome: 7 Cases and Literature Review. AJNR. American journal of neuroradiology, 36(7), 1355–1361. https://doi.org/10.3174/ajnr.A4297
10 Amara, S., Lopez, M., & Lebwohl, M. (2025). Improvement of Suspected Linear Morphea seen with Topical Ruxolitinib. SKIN The Journal of Cutaneous Medicine, 9(1), 2130–2133. https://doi.org/10.25251/skin.9.1.16
11 Flori, E., Cavallo, A., Mosca, S., Kovacs, D., Cota, C., Zaccarini, M., Di Nardo, A., Bottillo, G., Maiellaro, M., Camera, E., & Cardinali, G. (2024). JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines. Cells, 13(9), 760. https://doi.org/10.3390/cells13090760
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.